See more : Nextgreen Global Berhad (7241.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Tango Therapeutics, Inc. (TNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tango Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Karsan Otomotiv Sanayii ve Ticaret A.S. (KRSOF) Income Statement Analysis – Financial Results
- First Mining Gold Corp. (FFMGF) Income Statement Analysis – Financial Results
- PT Delta Djakarta Tbk (DLTA.JK) Income Statement Analysis – Financial Results
- Norway Royal Salmon AS (NRS.OL) Income Statement Analysis – Financial Results
- Neuberger Berman New York Municipal Fund, Inc. (NBO) Income Statement Analysis – Financial Results
Tango Therapeutics, Inc. (TNGX)
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Cost of Revenue | 115.20M | 4.03M | 1.97M | 1.63M | 32.27M |
| Gross Profit | -78.67M | 20.83M | 35.08M | 6.03M | -7.63M |
| Gross Profit Ratio | -215.38% | 83.80% | 94.69% | 78.77% | -30.93% |
| Research & Development | 115.20M | 105.91M | 77.64M | 49.99M | 32.27M |
| General & Administrative | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Other Expenses | 0.00 | 2.95M | 247.00K | 120.00K | 0.00 |
| Operating Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 7.15M |
| Cost & Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 39.43M |
| Interest Income | 6.62M | 1.46M | 495.00K | 108.00K | 684.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.42M | 4.03M | 1.97M | 1.63M | 643.00K |
| EBITDA | -111.76M | -109.46M | -57.29M | -51.48M | -14.52M |
| EBITDA Ratio | -305.96% | -446.79% | -157.09% | -672.44% | -58.90% |
| Operating Income | -114.17M | -111.07M | -58.19M | -52.20M | -15.16M |
| Operating Income Ratio | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Total Other Income/Expenses | 12.56M | 2.95M | 247.00K | 228.00K | 1.07M |
| Income Before Tax | -101.61M | -108.12M | -57.94M | -51.97M | -14.10M |
| Income Before Tax Ratio | -278.18% | -434.92% | -156.43% | -678.84% | -57.18% |
| Income Tax Expense | 134.00K | 54.00K | 292.00K | -108.00K | 0.00 |
| Net Income | -101.74M | -108.18M | -58.24M | -51.86M | -14.10M |
| Net Income Ratio | -278.54% | -435.14% | -157.21% | -677.43% | -57.18% |
| EPS | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Weighted Avg Shares Out | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
| Weighted Avg Shares Out (Dil) | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
Source: https://incomestatements.info
Category: Stock Reports